At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 3, 2026 at 12:00 ET
Indaptus Therapeutics announced the resignation of CFO Nir Sassi and the immediate appointment of Yu Ding as new CFO, along with the appointment of Qinglai Lu to the Board and Audit Committee. The leadership changes appear planned, with no disclosed disagreements, and bring fresh financial and Asia-Pacific market expertise to the company.
- CFO Nir Sassi resigned effective April 1, 2026, with no disclosed disagreement with the company
- Yu Ding appointed as new CFO effective immediately, bringing 20+ years of experience from CFO roles at Shanghai and Hong Kong-listed auto firms
- Qinglai Lu appointed to Board of Directors (effective April 8, 2026) and Audit Committee, with extensive finance and Web3 investment experience in Asia-Pacific
- Matthew McMurdo resigned from Audit Committee concurrent with Lu's appointment
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access